MoonLake Immunotherapeutics - Class A Ordinary Shares — Cash Flow (NASDAQ:MLTX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities —-611.07 K-55.89 M-42.78 M-116.59 M-196.01 M -224.15 M Cash from investing activities —0-32.34 M-25.18 M-205.6 M202.99 M 146.84 M Cash from financing activities —-58.06 K119.69 M479.7 M51.31 M146 M 103.52 M Free cash flow —-611.07 K-55.89 M-42.78 M-116.59 M-196.04 M -224.15 M

News

MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket

Clear Street raises Moonlake stock price target on IL-17 data

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake stock surges on positive axSpA trial data

MoonLake stock surges 63% after InvestingPro Fair Value call

MoonLake reports positive phase 2 axial spondyloarthritis data

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer

BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data